Katherine E. Yanosick

发表

Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate given via standard versus accelerated vaccination schedules: a phase 1, single-center, double-blind, sequential-group, randomized, placebo-controlled clinical trial

Joseph, N. Michael, D. Barouch, 2020 .

First-in-human evaluation of the safety and immunogenicity of a recombinant adenovirus serotype 26 HIV-1 Env vaccine (IPCAVD 001).

Jennifer A. Johnson, J. Goudsmit, D. Barouch, 2013, The Journal of infectious diseases.

First-in-Human Randomized, Controlled Trial of Mosaic HIV-1 Immunogens Delivered via a Modified Vaccinia Ankara Vector

Jennifer A. Johnson, B. Korber, P. Earl, 2018, The Journal of infectious diseases.

Safety and antiviral activity of triple combination broadly neutralizing monoclonal antibody therapy against HIV-1: a phase 1 clinical trial

Allan C. deCamp, J. Mascola, R. Koup, 2022, Nature Medicine.

Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19.

Ahmed Abdul Azim, D. Lauffenburger, H. Schuitemaker, 2021, JAMA.

Impact of anti-orthopoxvirus neutralizing antibodies induced by a heterologous prime-boost HIV-1 vaccine on insert-specific immune responses.

M. Seaman, R. Dolin, L. Baden, 2012, Vaccine.

Abstracts from the 4th Annual Student Medical Summit

Alisha, D. Ahern, J. Butler, 2021, BMC Proceedings.

Comparison of shortened mosaic HIV-1 vaccine schedules: a randomised, double-blind, placebo-controlled phase 1 trial (IPCAVD010/HPX1002) and a preclinical study in rhesus monkeys (NHP 17-22).

H. Schuitemaker, G. Alter, F. Wegmann, 2020, The lancet. HIV.

Safety and immunogenicity of a Zika purified inactivated virus vaccine given via standard, accelerated, or shortened schedules: a single-centre, double-blind, sequential-group, randomised, placebo-controlled, phase 1 trial.

Stephen J. Thomas, N. Michael, D. Barouch, 2020, The Lancet. Infectious diseases.

Poststudy Point-of-Care Oral Fluid Testing in Human Immunodeficiency Virus-1 Vaccinees

M. Seaman, R. Coombs, P. D’Souza, 2020, Open forum infectious diseases.